I. Introduction
W ITHIN the last decade, significant progress has been made in understanding the signaling pathways that underlie interactions between the endocrine and neural systems in the body. Paramount to achieving this progress was the recent recognition of the preeminent role of the neurotransmitter, glutamate, in the control of brain function. Due to its widespread localization at synapses in the brain and the large number of glutamate receptor subtypes found in the central nervous system (CNS), glutamate is recognized to be a central regulator of a large number of physiological processes in the body (Refs. 1-6, for review). Glutamate has also been implicated in a number of pathophysiological syndromes and diseases, such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, epilepsy, stroke, and brain injury. Several excellent reviews have appeared on the pathophysiological roles of glutamate, and the reader is referred to these articles for further information on this subject (7) (8) (9) (10) . Since glutamate receptors are localized in a variety of hypothalamic nuclei critical for reproduction and neuroendocrine function, it has been hypothesized that excitatory amino acids (EAAs) may play a critical role in the control of key reproductive and neuroendocrine processes such as puberty, pulsatility, the midcycle surge of gonadotropins, reproductive behavior, and stress. The present article will thus review the pertinent literature concerning EAAs and their possible role in these important reproductive and neuroendocrine events.
II. The EEA System: Overview, Description, and Localization in Neuroendocrine Tissues
With more than 23 receptor proteins (not including splice variants), four transporter proteins, and several possible endogenous ligands, the EAA neurotransmission system is an exceedingly complex system. However, by virtue of this diversity, it is well suited to fulfill the multiple regulatory roles for which it has been assigned in the CNS. Figure 1 illustrates the various components that comprise the EAA neurotransmission system. The three major components of the system (endogenous ligands, receptor proteins, and transporter proteins) will be discussed individually below.
A. Endogenous EAAs and their localization in the hypothalamus
1. Endogenous EAAs. The excitatory amino acid, glutamate, functions as the primary mediator of excitatory synaptic transmission in the CNS (1, 4, (11) (12) (13) (14) . Glutamate is stored in synaptic vesicles at the presynaptic terminal until it is released by depolarization in a Ca 2ϩ -dependent manner. Concentrations of glutamate in the synaptic cleft reportedly can reach millimolar levels (Refs. 15 and 16, for review). There is also evidence that aspartate is localized in synaptic vesicles in various parts of the brain and could function as a trans-mitter (17, 18) . Sulfur-containing acidic amino acids such as l-homocysteic acid, the tryptophan metabolite quinolinic acid, and the dipeptide N-acetyl-l-aspartyl-l-glutamic acid have also been identified in the brain, and there is some evidence supporting a role for them as excitatory neurotransmitters (12, 19, 20) . Nevertheless, the majority of the evidence available to date suggests that glutamate is the major endogenous EAA in the CNS that mediates excitatory synaptic neurotransmission through EAA receptors.
Glutamate exists as four different pools in the CNS: a transmitter pool, a metabolic pool, a glial pool, and a ␥-aminobutyric acid (GABA) precursor pool (21-23). Biochemical and immunocytochemical approaches have demonstrated that synaptic vesicle concentrations of glutamate (transmitter pool) are very high, approaching approximately 100 mm (21, 23) ( Fig. 1) . Average glial concentrations of glutamate, on the other hand, are much less (4 -5 mm), while glutamate concentrations in a GABAergic terminal are estimated to be from 9 -11 mm (21, 23). As also illustrated in Fig.   1 , glutamate is synthesized by several enzymes. The mitochondrial enzyme, phosphate-activated glutaminase (PAG), is thought to be an important glutamate biosynthetic enzyme in that it catalyzes the production of glutamate from glutamine and is present in both neurons and glia (21, 24). Phosphate and calcium activate PAG, while glutamate is inhibitory (24). Thus, in states of neuronal activation, which involves hydrolysis of ATP and increases of intracellular calcium, PAG activity would be expected to be up-regulated in the presynaptic neuron. The source of glutamine for neuronal production of glutamate appears to be glial cells since the biosynthetic enzyme for glutamine (glutamine synthetase) is found only in glial cells (25) (Fig. 1) . Glutamine synthetase serves to convert glutamate transported into glial cells into glutamine, which is then released to the extracellular space for uptake by neurons for use as a substrate for the PAG-driven production of glutamate (25). The enzymes aspartate aminotransferase and glutamate dehydrogenase have also been implicated to play a role in the synthesis of FIG. 1. Overview of the EAA system. The neurotransmitter glutamate is stored in synaptic terminals in the presynaptic neuron. Upon depolarization of the presynaptic neuron, glutamate is released from the presynaptic nerve terminals by exocytosis in an ATP-and calciumdependent manner. Once in the synaptic cleft, glutamate can bind to ionotropic EAA receptors (NMDA, Kainate, or AMPA) on the postsynaptic neuron. This results in activation of the ion channel associated with the EAA receptor to induce ion flux and depolarization of the postsynaptic neuron. Glutamate can also bind to metabotropic EAA receptors on the presynaptic neuron to prolong glutamate release. Termination of glutamate neurotransmission is thought to occur through removal of glutamate from the synaptic cleft by EAA transporter proteins (GLT-1, EAAC1), which are on glial and neuronal cells, respectively. Other transporters not illustrated in the diagram also exist: GLAST-1 and EAAC-4, which are described in the text. Abbreviations: AC, adenylate cyclase; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate; Asp, aspartate, Asp-AT, aspartate aminotransferase; Glu, glutamate; Gln, glutamine; GS, glutamine synthetase; mGluR, metabotropic EAA receptor; NMDA, N-methyl-D-aspartate; NO, nitric oxide; NOS, nitric oxide synthase; PAG, phosphate-activated glutaminase; PLC, phospholipase C. October, 1997 EXCITATORY AMINO ACIDS AND REPRODUCTIONglutamate (26, 27). Aspartate aminotransferase catalyzes the reversible reaction: aspartate ϩ 2-oxoglutarate 7 glutamate ϩ oxaloacetate, while glutamate dehydrogenase catalyzes the reversible reaction: glutamate ϩ NADP 7 2-oxoglutarate ϩ NH 3 ϩ NADPH ϩ Hϩ (22, 26, 27). The aspartate aminotransferase-and glutamate dehydrogenase-driven reactions are reversible, with the direction of the reactions determined by the concentration of substrates. Hence, aspartate aminotransferase and glutamate dehydrogenase can function either to synthesize or to metabolize glutamate.
Localization of EAAs in the hypothalamus.
A number of investigators have examined the distribution of glutamate in the hypothalamus of various species. These studies have revealed that within the hypothalamus of the rat and monkey, dense glutamate immunostaining is found in the magnocellular and parvocellular paraventricular nucleus (PVN), ventromedial nucleus (VMN), supraoptic nucleus (SON), lateral hypothalamic area, suprachiasmatic nucleus (SCN), arcuate nucleus (ARC), infundibular stalk, and median eminence (ME) (3, 17, 18, 28 -30) . The highest level of glutamate immunoreactivity was observed in presynaptic axon terminals, while astrocytic processes showed significantly less immunostaining (17) . As a whole, these immunolocalization studies demonstrated that glutamate is extensively localized in presynaptic terminals throughout the vast majority of the nuclei of the hypothalamus, and hence strategically positioned to control many different functions of the hypothalamus. Glutamate release from neuron terminals is through exocytosis, which is an ATP-and calcium-dependent event (31, 32). Current data suggest that glutamate exocytosis is due to calcium entry through calcium channels (Ref. 33, for review). Glutamate exocytosis can be modified by activation of facilitatory or inhibitory receptors on presynaptic neurons. Glutamate can enhance its own release by activation of the facilitatory metabotropic glutamate receptor on presynaptic neurons, which leads to phosphorylation and inactivation of presynaptic delayed rectifier K ϩ channels, enhanced calcium influx, and thus enhanced glutamate release (34). Agents that can inhibit glutamate exocytosis by acting at inhibitory presynaptic receptors include adenosine (35, 36), GABA-B agonists (37), and opioids (38). Once released into the synaptic cleft, glutamate can bind to specific EAA receptors on the pre-or postsynaptic neuron or it can be cleared from the synaptic cleft by either glial (GLT-1 or GLAST) or neuronal (EAAC1 or EAAT4) transporter proteins ( Fig. 1) , each of which will be discussed in sections below.
Regulation of EAA concentrations in the hypothalamus by steroid hormones and developmental changes.
Despite intense investigation, the specific factors that control EAA release at synaptic terminals remain poorly understood. Several laboratories have investigated the possibility that endocrine signals, such as steroid hormones, may be important regulators of EAA release in the hypothalamus. Regulation of hypothalamic EAA release by ovarian steroid hormones is of considerable interest to neuroendocrinologists as it could provide a potential mechanism for steroid hormone induction of hypothalamic GnRH release at midcycle, which produces the preovulatory LH surge. Microdialysis studies by Ping et al. (39) appear to support ovarian steroid hormone control of hypothalamic EAA release, as estrogen plus progesterone treatment in ovariectomized adult rats was found to significantly enhance the release rates of glutamate in the preoptic area (POA) of the hypothalamus 3-5 h after its administration (Fig. 2) . Aspartate release rates in the POA were also significantly enhanced by estrogen plus progesterone treatment. The release rates of the neurally inactive amino acid, serine, were not significantly affected by progesterone treatment, indicating that the changes in glutamate and aspartate were due to changes in neurotransmitter release and not to changes in metabolism. Since the increase in POA release rates of glutamate and aspartate occurred immediately before peak serum LH levels, it was proposed that the increased release of EAAs in the POA was necessary for activation of GnRH neurons. Work by Jarry et al. (40) also showed that the POA release rates of aspartate and glutamate are increased during the estrogen-induced LH surge. The steroid-induced increase in aspartate and glutamate release appears to occur only in the POA, as a recent study by Jarry et al. (41) demonstrated no change in aspartate or glutamate release in the mediobasal hypothalamus during the estrogeninduced LH surge. EAA levels in the hypothalamus have also been reported to be increased during puberty. Along these lines, Goroll et al. (42) recently demonstrated that the release rates of glutamate and aspartate are increased in the POA at the time of puberty in the female rat. Similarly, POA/mediobasal hypothalamus (MBH) concentrations of glutamate and aspartate have been reported to be higher in 30-day-old as compared with 16-day-old female rats (43). It is tempting to speculate that the elevations in hypothalamic EAA release rates observed during puberty are due to changes in circulating levels of ovarian steroids that are known to occur at the time of puberty. However, before definitive conclusions can be reached, further investigations are needed to establish whether the observed changes are actually due to fluctuations in steroids or to other puberty-related factors.
Other factors that have been demonstrated to modulate EAA release from the hypothalamus include the neurotransmitter GABA, which has been shown to stimulate glutamate release from rat POA neurosomes via a GABA A receptormediated mechanism (44). Glucocorticoids also appear to be major regulators of glutamate release in the brain, particularly in the hippocampus. For instance, Sapolsky and coworkers (45) have demonstrated that physiological elevations of glucocorticoids result in elevated release of glutamate in the hippocampus. This is intriguing because stress, which damages the hippocampus, has also been shown to result in significant enhancement of glutamate release in the hippocampus (46, 47). That the stress-induced elevation is mediated by glucocorticoids was evidenced by the finding that adrenalectomy eliminated the stress-induced rise in glutamate, while conversely, glucocorticoid replacement therapy reinstated the glutamate elevations in adrenalectomized animals (46, 47). The role of glutamate neurotransmission in the mediation of stress responses and modulation of the hypothalamic-pituitary-adrenal axis is discussed in more detail in a subsequent section (Section V.A.2).
B. Types of EAA receptors and their localization in the CNS and hypothalamus
1. Types of EAA receptors. EAA receptors are the most abundant excitatory neurotransmitter receptors in the CNS (1, 4, 6, 13) . They are also known as "glutamate receptors" since glutamate is believed to be the major endogenous ligand, although there may be other endogenous ligands as discussed above. Two principal groups of EAA receptors have been identified to date: 1) ionotropic and 2) metabotropic (Table 1) . Ionotropic receptors contain integral, cation-specific ion channels, whereas metabotropic receptors are coupled to G proteins and modulate the production of second messengers such as inositol phosphates and/or adenylate cyclase. Ionotropic receptors can be subdivided into 1) Nmethyl-d-aspartate (NMDA), 2) kainate, and 3) dl-␣-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors according to their selective agonists. Activation of ionotropic EAA receptors leads directly to the opening of a group of ion channels that are typified by their different permeabilities to Na ϩ , K ϩ , and Ca 2ϩ ions. Stimulation of these "ionotropic" receptors underlies rapid glutamate-mediated excitatory synaptic transmission in the CNS. Multiple subunits exist for each class of ionotropic EAA receptors as described in Table 1 , and it is thought that these subunits combine together to form a functional EAA receptor.
With molecular masses of 100,000 Da or more, the ionotropic EAA receptor subunits are quite large compared with most other ligand-gated channels (Refs. 1 and 48, for review). NMDA receptor channels are unique in that they are regulated by Mg 2ϩ and glycine. Mg 2ϩ binds to a site inside the NMDA receptor-coupled ion channel resulting in a block of the channel (49, 50). Glycine, on the other hand, is an allo-
Effect of progesterone upon POA release rates of glutamate (A) and serum LH serum (B) in the estrogenprimed ovariectomized adult rat. The animals were castrated for 2 weeks before use. Estradiol (5 g) was injected for 2 days followed by either vehicle (Veh) or progesterone (1 mg/rat) at 0900 h on the third day. Preoptic release rates of glutamate were determined by microdialysis. Perfusate samples were collected from the POA in 30-min fractions from 1200 h to 1730 h and analyzed by HPLC. Blood was collected hourly from a jugular cannula and LH levels were determined by RIA. E 2 , Estradiol-treated rats; E 2 ϩ P 4 , estradiol plus progesterone-treated rats. (12, 51) . With respect to AMPA receptors, the GluR2 subunit does not pass calcium through its channel, and it has a dominant effect when expressed with other GluR subunits in that the resultant channel also is impermeable to calcium (52, 53). Furthermore, each AMPA receptor subunit exists in two forms, termed "flip" and "flop," which are due to alternative splicing, and each form has different responses to agonists and different expression patterns in the brain (54). In contrast to the EAA ionotropic receptors described above, metabotropic receptors, on the other hand, do not activate ion channels. Instead, their response is characterized by a G protein-stimulated release of Ca 2ϩ from intracellular stores mediated by ITPs and modulation of adenylate cyclase activity (6, 14, 55) . Hence, metabotropic receptors exert prolonged synaptic modulation via modulation of second messenger systems. Metabotropic receptors have been divided into three groups based on agonist interactions and second messenger activation (Refs. 55 and 56, for review) ( Table 1) . Group 1 is comprised of mGluR1 and mGluR5 subunits due to the fact that they respond best to the ligand quisqualate, and their activation leads to enhanced phosphatidylinositol hydrolysis. Group 2 is comprised of mGluR2 and mGluR3 subunits based on the fact that they respond best to the ligand t-ACPD, and they inhibit cAMP formation. Finally, the mGluR4, mGluR6, mGluR7, and mGluR8 subunits comprise group 3 based on their responding best to the ligand L-AP4 and their inhibition of cAMP formation. Phenylglycine derivatives appear to selectively inhibit metabotropic receptors and may be useful in studying specific mGluR subunit effects and regulatory actions (Ref. 56, for review).
Localization of EAA receptors in neuroendocrine tissues.
For glutamate to be an important transmitter in neuroendocrine regulation, it would be essential for glutamate receptors to be localized in key neuroendocrine regulatory sites such as the hypothalamus and pituitary. As indicated in Table 1 Using polyclonal antibodies to AMPA type glutamate receptor subunits, Brann et al. (60) found that the AMPA GluR1 receptor subunit was moderately dense in the OVLT, ARC, SON, PVN, and SCN with lighter staining observed in the MPOA of the female rat. GluR2-3 antibody staining yielded a similar pattern to that of GluR1, while immunostaining for the GluR4 receptor showed only very light staining in the ARC and MPOA. AMPA GluR subunits, particularly GluR1 and GluR2, also appear to be widely distributed throughout the male rat hypothalamus (59). Kainate receptor localization has been less intensely studied in the hypothalamus, but kainate binding has been reported to be high in the ARC and ME of the monkey (76). The in situ distribution of kainate GluR6 mRNA is similar to the autoradiographic localization of kainate binding described above (62, 63), and kainate GluR5 subunit mRNA is also expressed in the rat hypothalamus with high levels reported in the SCN and moderate to low levels in the rest of the hypothalamus (62, 63).
With respect to metabotropic receptors, Van den Pol and co-workers (71, 72) have recently reported that the mGluR1 and mGluR5 subunits are strongly expressed in the rat POA, SCN, and lateral hypothalamus, while Petralia et al. (73) reported moderately dense mGluR2-3 immunostaining in the SON, and light to moderate immunostaining in other regions of the hypothalamus and the anterior pituitary.
In agreement with the rather wide distribution of EAA (79) found that estradiol plus progesterone treatment increases AMPA receptor GluR1 subunit immunoreactive levels in the POA and ARC of immature female rats. Diano et al. (80) also recently reported an up-regulation of GluR1 and GluR2-3 immunoprotein levels in the hypothalamus of the adult female rat after estradiol treatment. Thus, while hypothalamic NMDA receptors do not appear to be regulated by steroids, hypothalamic AMPA receptor levels, on the other hand, appear to be regulated by both estradiol and progesterone. To our knowledge, comparative studies examining whether steroids exert regulatory effects on kainate or metabotropic receptors in the hypothalamus have not been performed. Likewise, little is known concerning the specific cell types in the hypothalamus that possess EAA receptors, although Bhat et al. (74) recently reported that the NMDA-R1 receptor is colocalized in nitric oxide neurons in many hypothalamic nuclei of the female rat.
With respect to developmental changes in EAA receptors in the hypothalamus, Dees and co-workers (81) recently reported that NMDA-R1 mRNA levels increased at 20 days in the POA and at 25 days in the ARC/ME. Also, NMDA-R1 mRNA levels were reported to be increased in the POA during first proestrus in the rat. In contrast, Zamorano et al. (82) , using quantitative RT-PCR, showed only an increase in NMDA-R1 mRNA levels in the female rat POA at day 20, and no increase thereafter. Likewise, Gore et al. (83) found an increase in NMDA-R1 mRNA levels in the POA only on day 20. With respect to the MBH, Zamorano et al. (82) found that NMDA-R1 mRNA levels were increased at days 15, 20, and 25 in the female rat, with no increase observed thereafter. With respect to the AMPA GluR1 receptor, Zamorano et al. (82) found an increase in GluR1 mRNA levels in the MBH at day 15 in the female rat, followed by an increase in the POA at day 20, with no changes thereafter. Finally, EAA receptor binding studies by Brann et al. (67) found that neither NMDA nor kainate receptor binding changed in the hypothalamus of the female rat during the time of puberty. However, since these studies used a hypothalamic block, it is possible that changes in discrete nuclei could have been undetected. Obviously, further studies on developmental regulation of hypothalamic EAA receptors are needed.
Evidence that glutamate functions as a major excitatory transmitter in the hypothalamus.
Application of glutamate, aspartate, and l-homocysteic acid has been shown to excite neurons from virtually all areas tested in the hypothalamus including the ARC, ME, and other medial hypothalamic locations (84). Similarly, work by van den Pol and co-workers (3) demonstrated that hypothalamic neurons responded to glutamate, aspartate, kainate, and NMDA with an increase in intracellular Ca 2ϩ that mediates a wide variety of biochemical events in the cell. Furthermore, spontaneous excitatory postsynaptic potentials (EPSPs) in the ARC, PVN, and mPOA of the rat were found to be markedly attenuated by application of the non-NMDA receptor antagonist, cyano-3,3-dihydro-7-nitroquinoxaline (CNQX) (3). NMDA antagonists were found to only slightly suppress induced EPSPs; however, the test conditions were not suitable for the testing of NMDA since the membrane potential was maintained at hyperpolarized ranges that cause the NMDA current to be almost completely blocked. Thus, these studies demonstrated that EAA receptors in hypothalamic nuclei are functional and that glutamate is a major regulator of synaptic activation in the hypothalamus.
C. EAA transporters
Glutamate released into the synaptic cleft can be bound to receptors, or it can be removed by high-affinity glutamate transporters localized on neurons and glia. The removal of glutamate by transporter proteins prevents toxicity by removal of excess glutamate and allows for replenishment of glutamate transmitter stores through its recapture (Fig. 1 ). To date, four glutamate transporter proteins have been isolated from the brain. Two of the glutamate transporter proteins (GLAST and GLT-1) were isolated from glia (85, 86) while a third (EAAC1) was isolated from neurons (87) . The fourth (EAAT4) appears also to be a neuronal transporter and is predominantly expressed in the cerebellum (88) . For each glutamate transported into the cell by a transporter, two Naϩ
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are cotransported into the cell while a K ϩ and a OH Ϫ ion are transported out of the cell. Work from our laboratory has shown that the mRNA and protein for the GLT-1 and GLAST transporters are expressed in the cycling adult rat hypothalamus (R. Unda, V. B. Mahesh, and D. W. Brann, unpublished findings). EAAC1 has also been reported to be expressed in the hypothalamus, although only lightly (87) .
III. EAAs and Reproduction
Glutamate appears to play a central role in the regulation of reproduction by mediating steroid signals in the hypothalamus to control pituitary LH secretion. Evidence to support this contention has come from both agonist and antagonist studies and is supported by the previously described studies demonstrating that gonadal steroids enhance hypothalamic glutamate release during the time of the LH surge (39 -41), as well as enhances AMPA receptor levels in the hypothalamus (79, 80). The agonist and antagonist studies and the mechanisms and interactions of glutamate in the control of reproduction are discussed below.
A. Effect of EAA agonists on LH secretion
1. Glutamate. The first report demonstrating that glutamate can stimulate LH secretion came from the laboratories of Olney (89) and Ondo (90) (90) demonstrated that glutamate treatment markedly increased LH release in adult male rats without affecting FSH release. The effect of glutamate on LH secretion was suggested to be due to a hypothalamic site of action since direct pituitary injection of glutamate was found to have no effect on LH or FSH plasma levels (91) . Testosterone levels were also elevated in the male rats after subcutaneous glutamate treatment, presumably due to the elevations in LH (89) . Subsequent studies demonstrated that glutamate also was capable of stimulating LH secretion in the prepubertal male monkey (92) and the immature female rat (93).
NMDA.
The first report that selective agonists for the NMDA receptor (NMDA or NMA) could stimulate LH secretion originated from the laboratory of Cicero in 1978 (19) , in which NMA (N-methyl-d,l-aspartate) was demonstrated to stimulate LH secretion in immature male rats. The ability of NMDA to increase LH in male animals has been confirmed in a variety of species including rats (91, 94 -98) , monkeys (92, 99) , and hamsters (100, 101) . In female animals, numerous other studies have demonstrated that NMDA also stimulates LH secretion, and less consistently FSH secretion, in the intact immature female rat (43, 102, 103), the estrogen-primed ovariectomized rat and ewe (43, 93, 104 -106), as well as in the cycling female rat (107, 108) and monkey (109) (see also Fig. 3 ). Steroid hormones also appear to modulate NMDA effects on LH secretion, and this is discussed in detail in Section III A.6. below.
3. Kainate/AMPA. The effects of kainate on gonadotropin secretion have been less intensely investigated than those of NMDA; nevertheless, a small number of reports have appeared demonstrating that subcutaneous kainate administration elevates LH secretion in male rats (19, 91) , male monkeys (92) , and female rats (107) . The doses of kainate necessary for LH release (1-2.5 mg/kg body wt) are considerably less than those required for NMDA. As illustrated in Fig. 3 , central administration of kainate into the third cerebroventricle also enhances LH secretion in the ovariectomized estrogen-primed adult rat, suggesting that kainate probably acts at the level of the hypothalamus to control LH secretion. The effect of AMPA on LH release has not been studied extensively; however, there are recent reports demonstrating that AMPA increases LH release in the hamster (110) , ram (111) , and ovariectomized estrogen-primed adult female rat (Fig. 3) . Thus, activation of non-NMDA receptors also leads to enhanced LH secretion in a variety of species.
4. Metabotropic receptors. To our knowledge, there are no published reports describing activation of metabotropic receptors in the regulation of LH secretion. Since various metabotropic receptor subtypes have been demonstrated to be localized in important reproductive neuroendocrine nuclei of the hypothalamus (71-73), it is hoped that examination of this issue will be forthcoming in the near future.
Temporal and dose-dependent effects of EAAs on LH secretion.
NMDA, kainate, and AMPA regulation of LH secretion is rapid, with peak LH levels occurring 10 min after third intracerebroventricle (icv) injection in adult estrogen-primed ovariectomized rats (Fig. 3) . The effect is transient as LH levels typically return to baseline by 30 -60 min postinjection. The effect of EAAs on LH secretion is dose-dependent with effective icv doses ranging from 0.5-5 nmol for AMPA, kainate, and NMDA. Systemic injection (subcutaneous or intravenous) of EAA receptor agonists is also effective in eliciting a rapid release of LH (and in some cases of FSH), with effective doses ranging from 1-2.5 mg/kg body wt for kainate and AMPA and from 20 -40 mg/kg body wt for NMDA (19, 43, .
Steroid dependency of EAA effects on LH secretion.
Recent work by several laboratories has shown that the effect of NMDA on LH secretion is steroid-dependent. Comparable studies examining the steroid dependency of AMPA and kainate effects on LH secretion have not been performed to our knowledge. Concerning the steroid dependency of NMDA effects, NMDA has been shown to stimulate LH secretion in intact or steroid-primed ovariectomized animals, but it has no effect or is actually inhibitory to LH secretion in non-steroid-primed ovariectomized animals (93, 95, 106, 108, (112) (113) (114) . Subsequent studies by Arias et al. (113) found that NMDA stimulated GnRH release equally well from hypothalamic fragments obtained from either steroid-primed or non-steroid-primed ovariectomized rats. This suggests that the difference in LH response to NMDA may be due to different sensitivities of the anterior pituitary to released GnRH in the steroid-primed vs. the non-steroid-primed ovariectomized rat. In apparent support of this possibility, Kalra and co-workers (95) found that if one suppresses the hypersecretion of LH in the non-steroid-primed ovariectomized rat by giving an opioid agonist, then a stimulatory 684 BRANN AND MAHESH Vol. 18, No. 5 effect of NMDA on LH secretion could then be observed in the ovariectomized non-steroid-primed rat. Progesterone also appears to modulate EAA effects, as several groups have demonstrated that progesterone treatment significantly enhances the effect of NMDA on stimulating LH release in both the rat and the monkey (43, 112). Along these lines, Reyes et al. (112) found that the LH response to NMA was highest during the luteal phase of the monkey when serum progesterone levels were the highest. Likewise, Carbone et al. (43) found that NMDA administration induced plasma elevations of LH of 4.9-fold and 94.5-fold, respectively, in 30-day-old female rats and 30-day-old female rats treated with estrogen plus progesterone. How estradiol and progesterone may enhance LH response to EAAs is not entirely clear, but it could involve either an enhancement of pituitary sensitivity to GnRH, an enhance- Since the above studies were performed in discrete steroidreplaced ovariectomized animal models and one cannot be absolutely sure that the natural steroid fluctuations and patterns of the intact animal are exactly reproduced, it was important to confirm the above findings in the intact natural cycling adult rat. Toward this end, our laboratory examined the effect of an NMDA antagonist (MK-801) on the proestrous LH surge in the adult cycling rat. These studies showed that blockade of NMDA receptor-mediated neurotransmission via MK-801 treatment resulted in abolishment of the proestrous LH surge (104) . Mean FSH levels, on the other hand, were not statistically different in MK-801 vs. vehicle-treated proestrous rats. Non-NMDA receptors also appear to be important for production of the preovulatory LH surge as treatment of the PMSG-primed immature rat with the non-NMDA receptor antagonist DNQX (15 nmol at 1100 h and 1500 h on the day of the surge) significantly attenuated the preovulatory LH surge while having no effect on the FSH surge (118) . In agreement with our findings, Schwartz and co-workers (108) also found that the NMDA receptor antagonist MK-801 completely blocked the proestrous LH surge in the adult female rat. To our knowledge, there have been no studies reported in the literature concerning the role of metabotropic EAA receptors in LH surge production. This issue awaits further study. Nevertheless, taken as a whole, the above studies demonstrate that EAA neurotransmission through NMDA and non-NMDA receptors is an important component of the neurotransmission line mediating the natural preovulatory LH surge. (92, 107) . Additional support for a role of NMDA receptors in the control of pulsatile LH secretion has come from Arslan et al. (119) who found that systemic administration of a competitive NMDA receptor antagonist, AP5, suppresses pulsatile LH release in the castrate male rat. Similarly, Bourguignon et al. (120) found that pulsatile GnRH release from male hypothalami in vitro is abolished by MK-801 treatment. Work from our laboratory has demonstrated that a single icv administration of AP5 decreased LH and FSH mean and trough levels and LH and FSH pulse frequency in the castrate adult male rat (121) . In contrast, a single icv injection of the non-NMDA receptor antagonist, DNQX, did not have any effects on pulsatile LH or FSH secretion in the castrate adult male rat. However, if multiple injections of DNQX were used, then LH pulses were suppressed. In the ovariectomized female rat, icv administration of the NMDA receptor antagonist, AP5, or the non-NMDA receptor antagonist, DNQX, resulted in a significant decrease in mean and trough LH levels as well as LH pulse frequency and pulse amplitude (122) . Since DNQX blocks both kainate and AMPA receptors, the question arises which class of non-NMDA receptors is the more important in regulating pulsatile LH secretion. While this question awaits further experiments for its resolution, it should be pointed out that while kainate does stimulate LH secretion in male and female animals (19, 91, 92, 107) , its effect on LH release has been shown to rapidly desensitize, such that kainate stimulates LH secretion on the first application, but subsequent applications fail to cause elevations of LH secretion (92, 107) . Thus, attempts to show that kainate can induce pulsatile LH secretion have not been successful. To our knowledge, there are no published studies that have tested whether AMPA can induce pulsatile LH secretion. Likewise, the role of metabotropic EAA receptors in the control of pulsatile GnRH or LH secretion has not been thoroughly addressed. While further work in this area is clearly needed, the above studies do provide evidence that glutamate (acting through both NMDA and non-NMDA receptors) is able to modulate the natural pulse generator in the hypothalamus and thereby control pulsatile LH secretion in male and female animals. Thus, glutamate neurotransmission appears to be important for both surge and pulsatile LH secretion. Fig. 3 ) was demonstrated to induce a significant elevation of serum LH levels in male and female animals within 10 -15 min. A hypothalamic site of action is also supported by studies that demonstrated that GnRH antagonists block the ability of EAAs to stimulate LH release (96, 123, 124) . Conversely, direct injection of glutamate into the anterior pituitary was found to have no effect on LH secretion (90) . Likewise, NMDA was found to have no effect on LH release from rat anterior pituitary cells in static culture (125 Nevertheless, these studies require further confirmation, and the general consensus remains that glutamate controls LH secretion through actions exerted primarily at the hypothalamus of male and female animals.
Pulsatile LH secretion.
In addition to a role in LH surge expression, evidence has accumulated that EAAs have a regulatory role in the natural pulsatile pattern of LH secretion. Along these lines, repetitive NMDA stimulation has been demonstrated to produce GnRH pulses in vitro and LH pulses in vivo upon each stimulation
C. Site of action of EAAs in the control

Site of action of EAAs in the hypothalamus: POA vs. ARC/ME.
To pinpoint the sites in the brain where EAAs could act, several investigators have used c-Fos immunoreactivity as a marker of neuronal activation after EAA treatment. Along these lines, results from our laboratory demonstrated that administration of AMPA or kainate into the third ventricle of estrogen-primed ovariectomized adult rats induced immunoreactive c-Fos in the ARC (129) , suggesting that the ARC may be a major site of action for AMPA and kainate in the induction of LH release. In support of this suggestion, we found that AMPA and kainate are more potent than NMDA in stimulating GnRH release in vitro from proestrous rat ARC/ME fragments (130) . Likewise, Negro-Vilar and coworkers (131, 132) found that AMPA and kainate were much more potent than NMDA in stimulating GnRH release from male rat ARC/ME fragments. Finally, glutamate-induced GnRH release from male rat ARC/ME fragments in vitro was found to be blocked by the AMPA/kainate receptor antagonist, DNQX, but not by the NMDA receptor antagonist, AP-7 (131). Thus, non-NMDA receptors appear to be important in controlling LH secretion through actions at the level of the ARC/ME; however, it should be pointed out that kainate has been shown to stimulate LH release when injected into the POA (91), and kainate has also been demonstrated to stimulate GnRH mRNA levels in the POA of male rats (133) . Hence, one cannot rule out that non-NMDA receptor activation in the POA does not contribute to regulation of GnRH and LH secretion. With respect to NMDA induction of c-Fos in the brain, several groups have shown that NMDA induces c-Fos immunoreactivity in the ARC and ME, the OVLT, the periventricular hypothalamus, the PVN, the cerebral cortex, and in noradrenergic cells of the locus ceruleus of immature and adult rats (129, 134 -136) . These studies suggest that NMDA could act at multiple sites in or outside the hypothalamus to influence LH release. Considerable evidence has appeared in the literature suggesting that a major site of action of NMDA in the control of LH secretion is the POA of the hypothalamus. For instance, NMDA has been shown to stimulate LH secretion when injected into the MPOA, but not when injected into the anterior hypothalamic nucleus, ventromedial nucleus, or ARC (91), and NMDA is still capable of stimulating LH release even after destruction of the ARC by monosodium glutamate treatment (103, 137) . In addition, NMDA has been demonstrated to stimulate POA GnRH synthesis and secretion (120, 138) , and the elevation of GnRH mRNA levels in the POA corresponded with the NMDAinduced rise in plasma LH levels at 15 and 60 min (139). Liaw and Barraclough (140) confirmed and extended these findings to the female by demonstrating that NMDA administration increased OVLT/rostral POA GnRH mRNA levels at 1 h after injection in estrogen-primed ovariectomized rats. Finally, recent work by Bourguignon et al. (141) demonstrated that treatment with antisense oligonucleotides to the NMDA-R2A subunit inhibits pulsatile GnRH release from the complete POA/MBH fragment but not when the MBH fragment alone is used.
Based on the above findings, it is suggested that the POA constitutes a major site of action of NMDA in the regulation of GnRH and LH release; however, other sites, such as the locus ceruleus and ARC, may also be important contributing sites in mediating the regulatory actions of NMDA on GnRH and LH secretion. Figure 4 illustrates the potential different sites of action on which NMDA and non-NMDA receptors could be activated by glutamate to exert regulatory control over LH secretion. Based on the literature cited above, NMDA receptor-mediated actions are proposed to dominate in the POA, while non-NMDA receptor-mediated actions are proposed to dominate in the ARC/ME. The locus ceruleus may also be an additional important site of action for EAAs, since it provides a major catecholaminergic imput to the neuroendocrine hypothalamus, and NMDA has been shown to induce c-Fos in noradrenergic cell bodies in the locus ceruleus (136) . Recent studies have also demonstrated that NMDA and non-NMDA receptors are localized in the locus ceruleus (142) , and although there are conflicting reports in the literature, there is some evidence supporting a role for catecholamines in mediating NMDA effects on GnRH secretion, as will be discussed in detail in a subsequent section (20, 98, 103, 140, 143) . Finally, the anterior pituitary may also be a secondary site of action for EAAs, although this possibility requires further confirmation. (130 -132, 138, 143) . Comparatively little is known concerning the role of metabotropic receptors in the control of GnRH release. A single study in the literature addresses this issue, in which t-ACPD, a metabotropic EAA receptor agonist, was found to have no effect on GnRH release from male rat ARC/ME fragments in vitro (132). Zuo et al. (130) recently reported that middle-aged rats display an attenuated GnRH neurosecretory response to glutamate agonists on proestrus afternoon as compared with young proestrous rats (130) . This has led to the suggestion that a defect in hypothalamic glutamate neurosignaling may be an important contributing factor in reproductive aging in the female. The defect in hypothalamic glutamate neurosignaling may be due to a decrease in hypothalamic glutamate receptors as quantitative RT-PCR revealed significantly lower NMDA-R1 mRNA levels in the POA and ARC/ME of the middle-aged proestrous rat vs. the young proestrous rat (130).
D. Mechanism of action of EAAs in the control of LH secretion
EAAs control LH secretion by stimulating hypothalamic GnRH
EAA regulation of GnRH neurons: direct or indirect?
A major question concerning EAA regulation of GnRH secretion is whether the effect is exerted directly on the GnRH neuron or indirectly through interneurons. The majority of evidence supporting a direct effect of EAAs on GnRH neurons has come from studies utilizing the immortalized GnRH neuronal cell line (GT1-7 cell line). For instance, Spergel et al. (145) found that glutamate, NMDA, AMPA, kainate, and the metabotropic receptor agonist, t-ACPD, all were able to induce Ca 2ϩ influx and subsequent GnRH release in GT1-7 cells. The effects were reportedly specific as they were each blocked by specific EAA receptor antagonists. Similarly, Grumbach and co-workers (146) reported that NMDA stimulates GnRH release from GT1-7 cells in vitro, and they and others have reported that GT1-7 cells strongly express the (151) . Taken as a whole, the available in vivo data appear to support an indirect mechanism of action for EAAs in the control of GnRH secretion, although a direct effect on the GnRH neuron cannot be ruled out.
Potential mediators of EAA effects on GnRH neurons: a role for catecholamines?
Since the majority of the reports in the literature appear to support an indirect effect of EAAs to control GnRH neurosecretion, there has been intense work to identify "interneurons" that mediate EAA effects on GnRH neurons. Along these lines, a number of studies have demonstrated that EAAs can stimulate hypothalamic norepinephrine release in the rat (152) (153) (154) , leading to the suggestion that catecholamines may mediate the effects of EAAs on GnRH release. As stated previously, NMDA and non-NMDA receptors have been demonstrated in the locus ceruleus where many hypothalamic-projecting catecholamine cell bodies are located (142), and Saitoh et al. (136) reported that NMDA induces c-Fos in noradrenergic neurons of the locus ceruleus and in dopaminergic neurons in the MBH in the rat. In contrast, no c-Fos immunoreactivity was observed in neuropeptide Y-immunoreactive cells in the POA, septum, or locus ceruleus area after NMDA administration. Hence, either dopaminergic or noradrenergic neurons could play a role in mediating EAA effect on GnRH release. Liaw and Barraclough (140) reported that pretreatment with the ␣1-adrenergic antagonist, prazosin, blocked NMDA-induced LH release in four of seven rats. The remaining animals responded to NMDA with a significant increase in plasma LH. Studies utilizing norepinephrine synthesis inhibitors have also produced somewhat contradictory results, with a block of NMDA-induced LH release observed in one study (103) and no effect observed in a second study (20) . In vitro studies, on the other hand, have been more straightforward and less ambiguous as McCann and co-workers (143) found that phentolamine, a noradrenergic ␣-receptor antagonist, clearly and effectively blocked the ability of glutamate to stimulate GnRH release from male rat ARC/ME fragments in vitro. Dopamine appears to be less important than norepinephrine as a mediator of NMDA effects, as Price et al. (98) found that pretreatment with dopamine antagonists had no effect on NMA-induced LH release in the male rat. With respect to other potential mediators of glutamate action, Rossmanith et al. (155) recently demonstrated that administration of the NMDA receptor antagonist, MK-801, resulted in a significant attenuation of galanin mRNA levels in GnRH neurons during the time it blocked the steroidinduced LH surge in the rat. Since galanin is a potent stimulator of GnRH secretion and also has been implicated in the LH surge apparatus (156 -158) , it is possible that galanin neurons may also be a mediator of glutamate effects on GnRH neurons. Recent studies by Voight et al. (159) and Melcangi et al. (160) have also provided evidence that glial factors can facilitate GnRH secretion. This is interesting as glutamate receptors of all classes (excepting NMDA) have been demonstrated to be present on glial cells (161) , and glutamate has been shown to induce calcium waves in hypothalamic and hippocampal glial cells (18, 162, 163) . Thus, it is possible that in addition to recruiting other neurons into the accelerator mechanism for GnRH surge production, glutamate may also recruit and activate glial cells in the hypothalamus to release active factors to potentiate GnRH neurosecretion. This interesting possibility awaits further study.
Potential interaction of glutamate neurons with nitric oxide and opioid neurons in the hypothalamus: importance to the control of GnRH secretion.
Recent studies by a number of laboratories has provided significant evidence that the novel gaseous neurotransmitter, nitric oxide, plays an important role in mediating glutamate effects upon GnRH neurons (164, 165) . Work from our laboratory and others has demonstrated that nitric oxide neurons are present in significant concentrations in key reproductive hypothalamic nuclei including the OVLT, POA, and ME (74, 166, 167). GnRH neurons in the OVLT and POA of the male and female rat were found not to possess nitric oxide synthase (NOS); however, GnRH neurons were often surrounded by nitric oxide neurons, and potential contacts between the two neuronal types in the OVLT and POA were observed (74, 166, 167). Furthermore, there was a significant overlap between en passant GnRH neuronal fibers and nitric oxide neuronal fibers in the ME (74). Further work by our group has demonstrated that b-NOS (brain-NOS or neuronal-NOS) is the major NOS isoform in the hypothalamus with virtually no e-NOS (endothelial-NOS) or m-NOS (macrophage or inducible-NOS) detected (168). The above findings provide anatomical evidence that nitric oxide neurons are in position in the hypothalamus to regulate GnRH secretion and thus could serve to mediate glutamate effects on GnRH neurons.
That nitric oxide neurons in the hypothalamus could be targets for glutamate action was demonstrated by Bhat et al.
(74) who found that nitric oxide neurons in many hypothalamic nuclei appear to colocalize the NMDA-R1 receptor. Functional evidence supporting a role for nitric oxide in mediating glutamate stimulation of GnRH release has come from the study of Rettori et al. (164) , who demonstrated that glutamate-induced GnRH release from ARC/ME fragments in vitro is blocked by coadministration of a competitive inhibitor of nitric oxide, NG-monomethyl-l-arginine (NMMA) as well as by hemoglobin, which scavenges nitric oxide. Moreover, Moretto et al. (169) were the first to demonstrate that nitric oxide itself stimulates GnRH release from hypothalamic fragments and from immortalized GnRH neurons in vitro, a finding subsequently confirmed by McCann and While the mechanism of how nitric oxide mediates glutamate signals to induce GnRH release remains to be fully elucidated, it has been suggested that nitric oxide regulates cellular function by binding to and modulating the function of critical heme-containing signaling enzymes in cells. Along these lines, work from our laboratory has demonstrated that nitric oxide donors potently stimulate cGMP levels in the POA of the female rat (Fig. 6) (168) , and cGMP analogs have been shown to stimulate GnRH release, while a cGMP-dependent protein kinase inhibitor conversely blocks nitric oxide-induced GnRH release (169). Thus, nitric oxide may regulate the heme-containing signaling enzyme, guanylate cyclase, and thereby elevate the second messenger cGMP and facilitate GnRH secretion. Additionally, one cannot rule out an effect of nitric oxide on the heme-containing enzyme, cyclooxygenase, which controls production of prostaglandins, a known stimulator of GnRH secretion (173).
Preliminary studies suggest that glutamate neurons and nitric oxide neurons in the POA and MBH of the rat are tonically inhibited by opioid neurons, as evidenced by the finding that releasing the opioid brake in the hypothalamus by administration of the opioid antagonist, naloxone, leads to enhanced NOS activity in the POA and MBH preceding the naloxone-induced elevation in serum LH levels (174). The increase in nitric oxide in the hypothalamus is essential for the ability of naloxone to induce the LH surge as evidenced by the finding that pretreatment with an NOS inhibitor blocked the naloxone-induced LH surge. Prior treatment with a glutamate receptor antagonist was also found to block the naloxone-induced LH surge (174, 175) and naloxone-induced increase of hypothalamic NOS activity (174), suggesting that the opioid inhibition may be exerted on glutamate neurons, and that release of this opioid inhibition allows hypothalamic glutamate release and consequential activation of nitric oxide neurons. Thus, converging lines of evidence appear to support a role for nitric oxide as an important regulator of GnRH neurons and a critical mediator of glutamate action in the hypothalamus.
E. The opioid-glutamate-nitric oxide-guanylate cyclase pathway in the control of GnRH secretion: a proposed model
Based on the findings described above, a working model has been proposed that suggests a central role for glutamate in endocrine signaling to produce the preovulatory LH surge in the rat (Fig. 7) . As illustrated in the model, regulation of GnRH neurosecretion involves both inhibitory and excitatory neurotransmitters, which are regulated by steroid hormones. The inhibitory transmitters are proposed to function as a "brake" to restrain neurosecretion, whereas the excitatory transmitters are proposed to function as an "accelerator" to enhance GnRH neurosecretion. Opioid neurons are proposed to be the major component of the inhibitory brake, with GABA and neuropeptide K neurons also participating (95, 176 -185) . Based on the findings presented above, glutamate is proposed to be a major component of the "accelerator" mechanism, with nitric oxide, neuropeptide Y, galanin, and catecholamines also participating (2, 74, 79, 104, 155, 156, 164 -174, 186, 187) . During nonsurge conditions, the opioid inhibitory brake acts to tonically restrain GnRH secretion by inhibiting excitatory "accelerator" components such as glutamate (174, 175), catecholamine (188) , and neuropeptide Y (178, 185) neurons. Opioids may also directly inhibit GnRH neurons. During surge conditions, such as those observed on the day of the preovulatory LH surge, rising steroid hormone levels in the blood are proposed to exert actions in the brain to turn off opioid neurons, thereby allowing activation of excitatory "accelerator" components (glutamate, nitric oxide, neuropeptide Y, catecholamines, galanin), which stimulate GnRH neurons to produce the GnRH surge. As shown in the model, glial cells (astrocytes) may also participate in facilitating GnRH secretion (159, 160, 189) and may act to mediate glutamate-excitatory signals to GnRH neurons, although this requires further validation. As a whole, the evidence cited above clearly supports a critical and central role for glutamate as an important neuroendocrine signaler in the hypothalamus to control GnRH secretion and the preovulatory LH surge.
IV. Role of EAAs in Puberty and Reproductive Behavior
A. Role of EAAs in puberty
Due to its important role in regulating GnRH and LH secretion, it is perhaps not surprising that glutamate has been suggested to have a regulatory role in the achievement of puberty. Evidence supporting this contention was first provided by Urbanski and Ojeda (102) who reported in 1987 that NMDA administered as a 1-min pulse every 30 min for 5 h throughout the afternoons of postnatal days 26 -29 advanced puberty in the female rat by 7 days. This effect was extended to the monkey by Plant et al. (99) , who demonstrated that prolonged intermittent treatment with NMDA induced precocious puberty in the male rhesus monkey. Brann et al. (67) demonstrated that even shorter periods of intermittent NMDA treatment (90 min) were sufficient to advance puberty in the female rat. As shown in Fig. 8 , a remarkable degree of synchronization of the day of vaginal opening was observed in the NMDA-treated rats with the majority of the animals displaying vaginal opening on a single day (day 32). The non-NMDA receptor agonist, kainate (2 mg/kg), did not significantly affect the timing of puberty in the female rat 
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EXCITATORY AMINO ACIDS AND REPRODUCTION (Fig. 8) , and likewise treatment with the non-NMDA receptor antagonist, DNQX (15 nmol icv at 1400 and 1600 h, days 29 -36), had no significant effect on the time of vaginal opening in the female rat (67). In contrast, a physiological role for endogenous glutamate acting at NMDA receptors in puberty was evidenced by the demonstration that treatment with the NMDA receptor antagonist MK-801 delayed puberty in female rats (115) . Activation of GnRH neurons appears to underlie the ability of NMDA to advance puberty as evidenced by the ability of a GnRH antagonist to block the facilatory effect of NMDA on puberty (99) . Further support for a role for endogenous glutamate in the achievement of puberty has come from studies that have demonstrated that endogenous release rates for glutamate and aspartate increase in the POA in female rats at the time of puberty (42, 43). To our knowledge there have been no correlative studies performed to address whether AMPA or metabotropic EAA receptors play a role in puberty. Nevertheless, the above studies provide substantial evidence that endogenous glutamate acting through NMDA receptors is an important component in the CNS mechanism regulating puberty in female animals.
B. EAAs and reproductive behavior
Recent work by several groups has provided evidence that glutamate may regulate reproductive behavior in male and female animals (137, 144, 190 -193) . Gargiulo and Donoso (144) demonstrated that intraventricular injection of NMDA into estrogen-primed ovariectomized rats dose-dependently induced lordosis behavior and LH release. Prior treatment with a GnRH antagonist blocked the NMDA-induced LH release but had no effect upon NMDA induction of lordosis behavior. The stimulatory effect of NMDA on lordosis behavior also required an estrogen background as no effect was observed in non-estrogen-primed ovariectomized rats. Systemic administration of NMDA has also been reported to induce lordosis behavior in estrogen-primed ovariectomized rats (137) . It should be pointed out that there is not total agreement in the literature concerning glutamate regulation of lordosis behavior, as there have been a few reports suggesting that glutamate inhibits lordosis behavior (190, 191) . It is not clear why the various studies disagree; however, glutamate receptor antagonist studies appear to support a stimulatory role of glutamate in reproductive behavior. Along these lines, administration of the NMDA receptor antagonists, AP-5 or MK-801, significantly inhibited lordosis behavior in estrogen plus progesterone-treated ovariectomized rats (192) . In contrast, treatment with a non-NMDA receptor antagonist had no effect on lordosis behavior (192) . In male rats, treatment with MK-801 significantly reduced experience-based facilitation of mounting, such that experienced animals treated with MK-801 were found to behave similarly to inexperienced animals (193) . Taken as a whole, the above findings suggest that glutamate acting through NMDA receptors may mediate steroid signals in the CNS to facilitate reproductive behavior.
V. Role of EAAs in the Secretion of Other Anterior Pituitary Hormones
A. ACTH
Effect of EAAs on ACTH secretion.
In addition to regulating the hypothalamic-pituitary-gonadal axis, glutamate appears to be a major transmitter in the control of the hypothalamic-pituitary-adrenal (HPA) axis as well (Ref. 194 , for review). For instance, electrophysiological studies have demonstrated that administration of EAA antagonists inhibits almost completely synaptic responses in the magnocellular and parvocellular PVN, site of CRF and vasopressin cell bodies (195) . Since CRF and vasopressin are the major releasing factors that control ACTH secretion, it has been suggested that glutamate could play an important role in regulating the secretion of ACTH. In apparent support of this suggestion, recent studies have demonstrated that NMDA, kainate, and quisqualate are all capable of increasing plasma ACTH levels (97, 196 -198) . Effective doses for stimulation of ACTH release by EAAs ranged from 2.5-30 mg/kg in the different studies. There also appears to be developmental changes in the ability of NMDA to stimulate ACTH release. Along these lines, Brooks and Howe (199) found that ACTH response to NMDA increased with advancing gestational age in fetal sheep, with the highest response seen near term at gestational days 135-140. The authors speculate that NMDA receptors thus may be involved in the increased activation of the HPA axis during late gestation that leads to parturition. More studies are needed to address this interesting possibility. In addition to increasing ACTH release, EAAs have also been shown to markedly elevate corticosteroids within 30 min of administration in a variety of species (97, 112, 124, 197) . This effect is likely a secondary response to the ability of EAAs to enhance ACTH release. Fig. 9A , the PVN in the hypothalamus appears to be the major site of action for EAAs in regulating ACTH release since direct injection of glutamate into the PVN has been shown to stimulate ACTH release (200) . This effect appears to be due to EAA regulation of CRF release in the PVN since EAAs stimulate CRF release from neonatal rat hypothalami in vitro (201) . However, it should be pointed out that other studies failed to find any effect of EAAs on CRF release from adult rat hypothalami in vitro (202, 203) . Instead, EAAs stimulated the release of vasopressin, another ACTH-secretogue present in the PVN. However, immunoneutralization studies in rats have shown that CRF antiserum, but not vasopressin antiserum, blocks NMDA-and kainate-induced ACTH release in vivo (97, 197) . Finally, recent studies by Joanny et al. (204) revisted whether glutamate could modulate CRF release from adult rat hypothalami in vitro and found that glutamate and NMDA were capable of stimulating CRF release. Their study used hypothalamic slices rather than the fragments used in previous studies, which may have provided better access of the EAAs to the CRF neurons to stimulate CRF release. Thus, the available evidence to date tends to support regulation of CRF by EAAs as the primary mechanism of EAA stimulation of ACTH release, although other mechanisms such as modulation of arginine vasopressin release may also play a role (Fig. 9A) . Furthermore, glutamate may also exert effects at other CNS sites to modulate the HPA axis, as Gabr et al. (205) recently reported that direct injection of glutamate into the amygdala of stressed anesthetized male rats increased CRF release from the ME and markedly enhanced plasma corticosterone levels. Likewise, Carlson and Gann (206) demonstrated that direct injection of glutamate into the locus ceruleus also stimulates ACTH release. This effect may involve mediation by norepinephrine since the locus ceruleus is a major site of norepinephrine cell body localization that projects to the PVN, and EAAs have been reported to induce c-Fos in noradrenergic neurons in the locus ceruleus (136) . A direct effect of EAAs at the anterior pituitary seems unlikely since glutamate, NMDA, and kainate have been reported to have no effect on ACTH release from rat pituitaries incubated in vitro (197) . Recent work by several laboratories has provided evidence that EAAs may play a role in the activation of the HPA axis observed during stress. For instance, glutamate levels in the hippocampus have been reported to be elevated after different stress events (46, 47), and NMDA and AMPA receptor mRNA levels have also been reported to be elevated in the hippocampus and hypothalamus of the rat after immobilization stress (207) . Likewise, Yoneda et al. (208) found that immobilization stress enhanced NMDA receptor binding in the hypothalamus 24 h after immobilization, and this effect could be reproduced by exogenous administration of stress levels of corticosteroids.
A physiological role for EAAs in stress activation of the HPA axis was suggested from the studies of Jezova et al. (209) , who found that ACTH secretion in response to immobilization stress in male rats was significantly inhibited by pretreatment with the NMDA receptor antagonist, MK-801. Plasma epinephrine levels were also found to be inhibited by FIG. 9 . Proposed mechanisms/sites of action of EAAs in the control of ACTH (A), GH (B), and PRL (C) secretion. The proposed primary mechanism for EAA control of ACTH and GH, as suggested by studies in the literature, is illustrated by shading. There is no consensus in the literature concerning the primary mechanism of EAA control of PRL; therefore, there is no shading in panel C. GHRH, GH-releasing hormone (also known as GHRF); GHIH, GH-inhibiting hormone (also known as SRIF). See text for discussion.
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EXCITATORY AMINO ACIDS AND REPRODUCTIONMK-801 pretreatment. Similarly, Soltis and DiMicco (210) reported that microinjection of either a NMDA or non-NMDA receptor antagonist into the dorsomedial hypothalamus of adult male rats attenuated air stress-induced tachycardia, while Papp and Moryl (211) found that NMDA receptor antagonists reduced stress-induced depression. Thus, EAA neurotransmission appears to be an important activator of the HPA axis and may be a central mediator in stress responses.
B. GH
EAA regulation of GH release was first reported in 1983 by Mason et al. (212) , who demonstrated that subcutaneous injections of NMA or kainate, but not quisqualate, significantly elevated serum GH levels 7.5 min after administration in adult male rats. EAA stimulation of GH release was subsequently confirmed in a variety of species including sheep, bull calves, and monkeys (124, (213) (214) (215) . Additionally, Nemeroff et al. (216) found that intrahypothalamic injection of the NMDA receptor agonist, quinolinic acid, markedly stimulated GH release in male rats. As illustrated in Fig. 9B , stimulation of GHRF release from the ARC appears to be the major mechanism whereby NMDA stimulates GH release. Evidence supporting this contention has come from findings demonstrating that 1) NMDA-induced GH release can be blocked by administration of GHRF antibodies (215); 2) destruction of the ARC, where GHRF neuronal cell bodies reside, completely abolishes the ability of NMDA to induce GH release (215); 3) treatment of rats with an NMDA receptor antagonist causes a reduction in hypothalamic GHRF mRNA levels while somatostatin (SRIF) mRNA levels are unaltered (217); and 4) GHRF immunoreactivity in the ME is reduced in NMDA receptor antagonist-treated rats (217) . Other sites/ mechanisms still may have a regulatory role, however, as some studies have found a stimulatory effect of NMDA on SRIF release from hypothalami incubated in vitro (218) . Stimulation of SRIF could enhance GH release by exerting a regulatory effect on GHRF release in the ARC (218, 219) . As also shown in Fig. 9B , in addition to a hypothalamic site of action, EAAs may also act directly at the anterior pituitary to regulate GH secretion. In support of this possibility, NMDA has been shown to dose-dependently stimulate GH secretion from perifused somatotropes in vitro (127) . This effect was blocked by treatment with NMDA receptor antagonists and appeared to be mediated by an increase in intracellular calcium. Niimi et al. (220) also confirmed a dose-dependent stimulatory effect of NMDA, kainate, and glutamate on GH release from somatotropes in vitro. Thus, while EAA regulation of GHRF release from the ARC appears to be the primary mechanism for EAA stimulation of GH release, other sites and mechanisms may also play a role.
C. PRL
Recent work has shown that NMDA treatment induces c-Fos immunoreactivity in hypothalamic regions known to be important in the regulation of PRL secretion (i.e., the PVN and the ARC) (107, 135) . Agonist studies verified that NMDA treatment leads to enhanced PRL secretion in male and female animals of a variety of species (96, 107-109, 124, 221) . Kainate also stimulates PRL release when administered into the third cerebroventricle (107) . The mechanism whereby EAAs stimulate PRL release is presently unclear. As shown in Fig. 9C , EAAs could act to enhance PRL secretion through effects on PRL-releasing factors in the hypothalamus, such as TRH and vasoactive intestinal peptide in the PVN or oxytocin in the ARC. Dopamine neurons in the ARC may also play a role in EAA stimulation of PRL release, as NMDA has been reported to induce c-Fos immunoreactivity in dopamine neurons in the MBH (136) . Glutamate and NMDA have also been reported to enhance PRL release directly from perifused anterior pituitary cells in vitro (128) , suggesting that direct modulation by glutamate at the anterior pituitary is also possible. Clearly, more studies are needed to clarify the precise site and mechanism of action of EAAs in the stimulation of PRL release.
Work by a number of investigators has addressed the question of whether glutamate neurotransmission has a physiological role in the control of PRL secretion (104, 118, 222, 223) . Brann and Mahesh (104) demonstrated that administration of the NMDA receptor antagonist, MK-801, blocks the proestrous PRL surge in the female rat as well as the PMSG-induced preovulatory PRL surge in the immature female rat. Non-NMDA receptors also appear to be important for the preovulatory PRL surge, as Brann et al. (118) have shown that injection of the non-NMDA receptor antagonist DNQX into the third cerebroventricle also significantly attenuates the preovulatory PRL surge in the PMSG-primed immature rat. Non-NMDA antagonist treatment was also shown to attenuate suckling-induced PRL release, an effect not shared by NMDA receptor antagonists (223) . As a whole, the above studies provide significant evidence that glutamate is an important transmitter in the control of PRL secretion.
VI. Conclusions
As evidenced by the findings presented in this review, a tremendous amount of progress has been achieved in the last 7-8 yr toward understanding the contributions and importance of glutamate in endocrine signaling. Abundant evidence has accumulated in the literature that demonstrates that glutamate, acting primarily within the hypothalamus, regulates a host of hypothalamic releasing factors (GnRH, CRF, GHRF, and SRIF) that serve to control the secretion of a variety of anterior pituitary hormones (ACTH, LH, FSH, PRL, and GH). Thus, glutamate through its control of these pituitary hormones, serves to regulate most, if not all, the major physiological systems of the body. In turn, glutamate and its receptors are subject to regulation by endocrine chemical messengers such as steroid hormones, thus completing the feedback circuit.
Although much has been accomplished, significant gaps still remain in our knowledge. For instance, while there is considerable knowledge and understanding with respect to the role of NMDA receptors in neuroendocrine regulation, considerably less is known concerning the role of AMPA and kainate receptors in these events, and virtually nothing is 
